Nilanjan Ghosh MD, PhD, Levine Cancer Institute, Charlotte, NC, provides an overview of results of the final analysis of a Phase Ib/II trial of obinutuzumab-atezolizumab-lenalidomide for relapsed/refractory (R/R) follicular lymphoma. Dr Ghosh gives an overview of the study design and the observed safety profile. The 36-month progression-free survival rate was 68.4% and the overall survival rate was 90%. Achievement of measurable residual disease (MRD)-negativity was strongly associated with complete response. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.